Makers Should Venture into Drug Development Using iPS, CiRA Adviser Asonuma Says

CiRA Adviser Shinji Asonuma at Interview Pharmaceutical companies should consider harnessing induced pluripotent stem (iPS) cells for their new drug development, says Shinji Asonuma, former vice health minister and now adviser of Kyoto University’s Center for iPS Cell Research and...read more